References for U.S. SPR, 2024

At a glance

This page provides references for the 2024 U.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR). The U.S. SPR provides recommendations for health care providers that address a selected group of common, yet sometimes complex, issues regarding initiation and use of specific contraceptive methods.

References

  1. Nguyen AT, Curtis KM, Tepper NK, et al. U.S. medical eligibility criteria for contraceptive use, 2024. MMWR Recomm Rep 2024;73(No. RR-4):1–126.
  2. World Health Organization. Medical eligibility criteria for contraceptive use. Geneva, Switzerland: World Health Organization; 2015. https://www.who.int/publications/i/item/9789241549158
  3. World Health Organization. Selected practice recommendations for contraceptive use. Geneva, Switzerland: World Health Organization; 2016. https://www.who.int/publications/i/item/9789241565400
  4. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC. U.S. selected practice recommendations for contraceptive use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. MMWR Recomm Rep 2013;62(No. RR-5):1–60. PMID:23784109
  5. Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep 2016;65:1–66. PMID:27467319 https://doi.org/10.15585/mmwr.rr6504a1
  6. Gavin L, Moskosky S, Carter M, et al.; CDC. Providing quality family planning services: recommendations of CDC and the U.S. Office of Population Affairs. MMWR Recomm Rep 2014;63(No. RR-4):1–54. PMID:24759690
  7. Gavin L, Pazol K. Update: providing quality family planning services—recommendations from CDC and the U.S. Office of Population Affairs, 2015. MMWR Morb Mortal Wkly Rep 2016;65:231–4. PMID:26963363 https://doi.org/10.15585/mmwr.mm6509a3
  8. Gavin L, Pazol K, Ahrens K. Update: providing quality family planning services—recommendations from CDC and the U.S. Office of Population Affairs. MMWR Morb Mortal Wkly Rep 2017;66:1383–5. PMID:29267259 https://doi.org/10.15585/mmwr.mm6650a4
  9. United Nations Population Fund. Programme of action of the International Conference on Population and Development. Cairo, Egypt: United Nations; September 5–13, 1994. https://unfpa.org/sites/default/files/pub-pdf/programme_of_action_Web%20ENGLISH.pdf
  10. American College of Obstetricians and Gynecologists’ Committee on Health Care for Underserved Women, Contraceptive Equity Expert Work Group, and Committee on Ethics. Patient-centered contraceptive counseling: ACOG Committee Statement Number 1. Obstet Gynecol 2022;139:350–3. PMID:35061341 https://doi.org/10.1097/AOG.0000000000004659

    11. Back to Top

  11. American Public Health Association. Opposing coercion in contraceptive access and care to promote reproductive health equity. Policy No. 202110: American Public Health Association; 2021 October 26, 2021. https://apha.org/Policies-and-Advocacy/Public-Health-Policy-Statements/Policy-Database/2022/01/07/Opposing-Coercion-in-Contraceptive-Access-and-Care-to-Promote-Reproductive-Health-Equity
  12. World Health Organization. Framework for ensuring human rights in the provision of contraceptive information and services. Geneva, Switzerland: World Health Organization; 2014. https://iris.who.int/bitstream/handle/10665/133327/9789241507745_eng.pdf
  13. Holt K, Reed R, Crear-Perry J, Scott C, Wulf S, Dehlendorf C. Beyond same-day long-acting reversible contraceptive access: a person-centered framework for advancing high-quality, equitable contraceptive care. Am J Obstet Gynecol 2020;222:S878.e1, 878.e6. PMID:31809706 https://doi.org/10.1016/j.ajog.2019.11.1279
  14. Curtis KM, Nguyen A, Reeves JA, Clark EA, Folger SG, Whiteman MK. Update to U.S. selected practice recommendations for contraceptive use: self-administration of subcutaneous depot medroxyprogesterone acetate. MMWR Morb Mortal Wkly Rep 2021;70:739–43. PMID:34014910 https://doi.org/10.15585/mmwr.mm7020a2
  15. Mohllajee AP, Curtis KM, Flanagan RG, Rinehart W, Gaffield ML, Peterson HB. Keeping up with evidence a new system for WHO’s evidence-based family planning guidance. Am J Prev Med 2005;28:483–90. PMID:15894153 https://doi.org/10.1016/j.amepre.2005.02.008
  16. CDC. Updating CDC’s contraception guidance documents: U.S. medical eligibility criteria for contraceptive use and U.S. selected practice recommendations for contraceptive use. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https://www.govinfo.gov/content/pkg/FR-2021-08-31/pdf/2021-18769.pdf
  17. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. PMID:33782057 https://doi.org/10.1136/bmj.n71
  18. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383–94. PMID:21195583 https://doi.org/10.1016/j.jclinepi.2010.04.026
  19. Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6. PMID:18436948 https://doi.org/10.1136/bmj.39489.470347.AD
  20. Steenland MW, Rodriguez MI, Marchbanks PA, Curtis KM. How does the number of oral contraceptive pill packs dispensed or prescribed affect continuation and other measures of consistent and correct use? A systematic review. Contraception 2013;87:605–10. PMID:23040121 https://doi.org/10.1016/j.contraception.2012.08.004

    21. Back to Top

  21. Steenland MW, Zapata LB, Brahmi D, Marchbanks PA, Curtis KM. Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review. Contraception 2013;87:611–24. PMID:23177264 https://doi.org/10.1016/j.contraception.2012.09.017
  22. Steenland MW, Zapata LB, Brahmi D, Marchbanks PA, Curtis KM. The effect of follow-up visits or contacts after contraceptive initiation on method continuation and correct use. Contraception 2013;87:625–30. PMID:23114736 https://doi.org/10.1016/j.contraception.2012.09.018
  23. Tepper NK, Curtis KM, Steenland MW, Marchbanks PA. Physical examination prior to initiating hormonal contraception: a systematic review. Contraception 2013;87:650–4. PMID:23121820 https://doi.org/10.1016/j.contraception.2012.08.010
  24. Tepper NK, Steenland MW, Marchbanks PA, Curtis KM. Laboratory screening prior to initiating contraception: a systematic review. Contraception 2013;87:645–9. PMID:23040133 https://doi.org/10.1016/j.contraception.2012.08.009
  25. Harris RP, Helfand M, Woolf SH, et al.; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001;20(Suppl):21–35. PMID:11306229 https://doi.org/10.1016/S0749-3797(01)00261-6
  26. World Health Organization. Selected practice recommendations for contraceptive use, 2nd ed. Geneva, Switzerland: WHO Press; 2004.
  27. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: The National Academies Press; 2001.
  28. Bradley SEK, Polis CB, Micks EA, Steiner MJ. Effectiveness, safety, and comparative side effects. In: Cason P CC, Edelman A, Kowal D, Marrazzo JM, Nelson AL, Pollicar MS, Hatcher RA, eds. Contraceptive technology. 22nd ed. Burlington, MA: Jones-Bartlett Learning; 2023.
  29. Potter JE, Stevenson AJ, Coleman-Minahan K, et al. Challenging unintended pregnancy as an indicator of reproductive autonomy. Contraception 2019;100:1–4. PMID:30851238 https://doi.org/10.1016/j.contraception.2019.02.005
  30. Reproductive Health National Training Center. Contraceptive counseling and education eLearning; 2022. https://rhntc.org/resources/contraceptive-counseling-and-education-elearning

    31. Back to Top

  31. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep 2021;70:1–187. PMID:34292926 https://doi.org/10.15585/mmwr.rr7004a1
  32. CDC. US Public Health Service preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
  33. Stanback J, Nakintu N, Qureshi Z, Nasution M. Does assessment of signs and symptoms add to the predictive value of an algorithm to rule out pregnancy? J Fam Plann Reprod Health Care 2006;32:27–9. PMID:16492334 https://doi.org/10.1783/147118906775275370
  34. Stanback J, Nanda K, Ramirez Y, Rountree W, Cameron SB. Validation of a job aid to rule out pregnancy among family planning clients in Nicaragua. Rev Panam Salud Publica 2008;23:116–8. PMID:18371282 https://doi.org/10.1590/S1020-49892008000200007
  35. Stanback J, Qureshi Z, Sekadde-Kigondu C, Gonzalez B, Nutley T. Checklist for ruling out pregnancy among family-planning clients in primary care. Lancet 1999;354:566. PMID:10470704 https://doi.org/10.1016/S0140-6736(99)01578-0
  36. Torpey K, Mwenda L, Kabaso M, et al. Excluding pregnancy among women initiating antiretroviral therapy: efficacy of a family planning job aid. BMC Public Health 2010;10:249. PMID:20470367 https://doi.org/10.1186/1471-2458-10-249
  37. Cole LA, Ladner DG, Byrn FW. The normal variabilities of the menstrual cycle. Fertil Steril 2009;91:522–7. PMID:18433748 https://doi.org/10.1016/j.fertnstert.2007.11.073
  38. Wilcox AJ, Dunson D, Baird DD. The timing of the “fertile window” in the menstrual cycle: day specific estimates from a prospective study. BMJ 2000;321:1259–62. PMID:11082086 https://doi.org/10.1136/bmj.321.7271.1259
  39. Donnet ML, Howie PW, Marnie M, Cooper W, Lewis M. Return of ovarian function following spontaneous abortion. Clin Endocrinol (Oxf) 1990;33:13–20. PMID:2401092 https://doi.org/10.1111/j.1365-2265.1990.tb00460.x
  40. Lähteenmäki P. Postabortal contraception. Ann Med 1993;25:185–9. PMID:8489759 https://doi.org/10.3109/07853899309164166

    41. Back to Top

  41. Stoddard A, Eisenberg DL. Controversies in family planning: timing of ovulation after abortion and the conundrum of postabortion intrauterine device insertion. Contraception 2011;84:119–21. PMID:21757051 https://doi.org/10.1016/j.contraception.2010.12.010
  42. Jackson E, Glasier A. Return of ovulation and menses in postpartum nonlactating women: a systematic review. Obstet Gynecol 2011;117:657–62. PMID:21343770 https://doi.org/10.1097/AOG.0b013e31820ce18c
  43. Kennedy KI, Rivera R, McNeilly AS. Consensus statement on the use of breastfeeding as a family planning method. Contraception 1989;39:477–96. PMID:2656086 https://doi.org/10.1016/0010-7824(89)90103-0
  44. Labbok MH, Perez A, Valdes V, et al. The lactational amenorrhea method (LAM): a postpartum introductory family planning method with policy and program implications. Adv Contracept 1994;10:93–109. PMID:7942265 https://doi.org/10.1007/BF01978103
  45. Food and Drug Administration. 510(k) premarket notification. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2015. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
  46. Cervinski MA, Gronowski AM. Reproductive-endocrine point-of-care testing: current status and limitations. Clin Chem Lab Med 2010;48:935–42. PMID:20446758 https://doi.org/10.1515/CCLM.2010.183
  47. Cole LA. Human chorionic gonadotropin tests. Expert Rev Mol Diagn 2009;9:721–47. PMID:19817556 https://doi.org/10.1586/erm.09.51
  48. Eichner SF, Timpe EM. Urinary-based ovulation and pregnancy: point-of-care testing. Ann Pharmacother 2004;38:325–31. PMID:14742773 https://doi.org/10.1345/aph.1D210
  49. Wilcox AJ, Baird DD, Dunson D, McChesney R, Weinberg CR. Natural limits of pregnancy testing in relation to the expected menstrual period. JAMA 2001;286:1759–61. PMID:11594902 https://doi.org/10.1001/jama.286.14.1759
  50. Korhonen J, Alfthan H, Ylöstalo P, Veldhuis J, Stenman UH. Disappearance of human chorionic gonadotropin and its alpha- and beta-subunits after term pregnancy. Clin Chem 1997;43:2155–63. PMID:9365402 https://doi.org/10.1093/clinchem/43.11.2155

    51. Back to Top

  51. Reyes FI, Winter JS, Faiman C. Postpartum disappearance of chorionic gonadotropin from the maternal and neonatal circulations. Am J Obstet Gynecol 1985;153:486–9. PMID:4061509 https://doi.org/10.1016/0002-9378(85)90458-2
  52. Steier JA, Bergsjø P, Myking OL. Human chorionic gonadotropin in maternal plasma after induced abortion, spontaneous abortion, and removed ectopic pregnancy. Obstet Gynecol 1984;64:391–4. PMID:6462569
  53. Bracken MB. Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies. Obstet Gynecol 1990;76:552–7. PMID:2143279
  54. Gray RH, Pardthaisong T. In utero exposure to steroid contraceptives and survival during infancy. Am J Epidemiol 1991;134:804–11. PMID:1835283 https://doi.org/10.1093/oxfordjournals.aje.a116153
  55. Pardthaisong T, Gray RH. In utero exposure to steroid contraceptives and outcome of pregnancy. Am J Epidemiol 1991;134:795–803. PMID:1835282 https://doi.org/10.1093/oxfordjournals.aje.a116152
  56. Jaffe B, Harlap S, Baras M, et al. Long-term effects of MPA on human progeny: intellectual development. Contraception 1988;37:607–19. PMID:2969321 https://doi.org/10.1016/0010-7824(88)90007-8
  57. Pardthaisong T, Yenchit C, Gray R. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation. Contraception 1992;45:313–24. PMID:1387602 https://doi.org/10.1016/0010-7824(92)90053-V
  58. Brahmi D, Steenland MW, Renner RM, Gaffield ME, Curtis KM. Pregnancy outcomes with an IUD in situ: a systematic review. Contraception 2012;85:131–9. PMID:22067777 https://doi.org/10.1016/j.contraception.2011.06.010
  59. Tepper NK, Marchbanks PA, Curtis KM. Use of a checklist to rule out pregnancy: a systematic review. Contraception 2013;87:661–5. PMID:23040127 https://doi.org/10.1016/j.contraception.2012.08.007
  60. James SE, Herman JL, Rankin S, Keisling M, Mottet L, Anafi M. The report of the 2015 U.S. Transgender Survey. Washington, DC: National Center for Transgender Equality; 2016. https://transequality.org/sites/default/files/docs/usts/USTS-Full-Report-Dec17.pdf

    61. Back to Top

  61. Moseson H, Fix L, Hastings J, et al. Pregnancy intentions and outcomes among transgender, nonbinary, and gender-expansive people assigned female or intersex at birth in the United States: results from a national, quantitative survey. Int J Transgender Health 2021;22:30–41. PMID:34796363 https://doi.org/10.1080/26895269.2020.1841058
  62. Slayback Pharma. Testosterone cypionate injection [Package insert]. Princeton, NJ: Slayback Pharma; 2022.
  63. Coleman E, Radix AE, Bouman WP, et al. Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgender Health 2022;23(Suppl 1):S1–259. PMID:36238954 https://doi.org/10.1080/26895269.2022.2100644
  64. American College of Obstetricians and Gynecologists. Health care for transgender and gender diverse individuals: ACOG Committee Opinion, Number 823. Obstet Gynecol 2021;137:e75–88. PMID:33595253 https://doi.org/10.1097/AOG.0000000000004294
  65. American Society for Emergency Contraception. Emergency contraception for transgender and nonbinary patients; 2021. https://www.americansocietyforec.org/_files/ugd/0cdab4_c14646d8a1e3407688563f1c24f4bd77.pdf
  66. Bonnington A, Dianat S, Kerns J, et al. Society of Family Planning clinical recommendations: contraceptive counseling for transgender and gender diverse people who were female sex assigned at birth. Contraception 2020;102:70–82. PMID:32304766 https://doi.org/10.1016/j.contraception.2020.04.001
  67. Brandt JS, Eichelberger KY, Wong MS; Society for Maternal-Fetal Medicine (SMFM). Society for Maternal-Fetal Medicine special statement: commitment to excellence in obstetrical care, research, and education for people with diverse sexual and gender identities. Am J Obstet Gynecol 2022;226:B10–2. PMID:34785176 https://doi.org/10.1016/j.ajog.2021.11.1344
  68. Taub RL, Ellis SA, Neal-Perry G, Magaret AS, Prager SW, Micks EA. The effect of testosterone on ovulatory function in transmasculine individuals. Am J Obstet Gynecol 2020;223:229.e1–8. PMID:32044312 https://doi.org/10.1016/j.ajog.2020.01.059
  69. Whiteman MK, Tyler CP, Folger SG, Gaffield ME, Curtis KM. When can a woman have an intrauterine device inserted? A systematic review. Contraception 2013;87:666–73. PMID:22995537 https://doi.org/10.1016/j.contraception.2012.08.015
  70. Cooper Surgical. ParaGard (T 380A intrauterine copper contraceptive) [Package insert]. Trumbull, CT: Cooper Surgical; 2019.

    71. Back to Top

  71. Bayer HealthCare Pharmaceuticals. Mirena (levonorgestrel-releasing intrauterine system) [Package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; 2022.
  72. Bayer HealthCare Pharmaceuticals. Skyla (levonorgestrel-releasing intrauterine system) [Package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; 2021.
  73. Bayer HealthCare Pharmaceuticals. Kyleena (levonorgestrel-releasing intrauterine system) [Package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; 2023.
  74. Jatlaoui TC, Simmons KB, Curtis KM. The safety of intrauterine contraception initiation among women with current asymptomatic cervical infections or at increased risk of sexually transmitted infections. Contraception 2016;94:701–12. PMID:27263041 https://doi.org/10.1016/j.contraception.2016.05.013
  75. Avonts D, Sercu M, Heyerick P, Vandermeeren I, Meheus A, Piot P. Incidence of uncomplicated genital infections in women using oral contraception or an intrauterine device: a prospective study. Sex Transm Dis 1990;17:23–9. PMID:2305333 https://doi.org/10.1097/00007435-199017010-00006
  76. Birgisson NE, Zhao Q, Secura GM, Madden T, Peipert JF. Positive testing for Neisseria gonorrhoeae and Chlamydia trachomatis and the risk of pelvic inflammatory disease in IUD users. J Womens Health (Larchmt) 2015;24:354–9. PMID:25836384 https://doi.org/10.1089/jwh.2015.5190
  77. Campbell SJ, Cropsey KL, Matthews CA. Intrauterine device use in a high-risk population: experience from an urban university clinic. Am J Obstet Gynecol 2007;197:193.e1–6, discussion 193.e6–7. PMID:17689646 https://doi.org/10.1016/j.ajog.2007.04.028
  78. Cropsey KL, Matthews C, Campbel S, Ivey S, Adawadkar S. Long-term, reversible contraception use among high-risk women treated in a university-based gynecology clinic: comparison between IUD and depo-provera. J Womens Health (Larchmt) 2010;19:349–53. PMID:20109106 https://doi.org/10.1089/jwh.2009.1518
  79. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785–8. PMID:1347812 https://doi.org/10.1016/0140-6736(92)91904-M
  80. Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database Syst Rev 2001;CD001327. PMID:10796777 https://doi.org/10.1002/14651858.CD001327

    81. Back to Top

  81. LeFevre ML; US Preventive Services Task Force. Screening for chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:902–10. PMID:25243785 https://doi.org/10.7326/M14-1981
  82. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception 2006;73:145–53. PMID:16413845 https://doi.org/10.1016/j.contraception.2005.08.007
  83. Morrison CS, Turner AN, Jones LB. Highly effective contraception and acquisition of HIV and other sexually transmitted infections. Best Pract Res Clin Obstet Gynaecol 2009;23:263–84. PMID:19211309 https://doi.org/10.1016/j.bpobgyn.2008.11.004
  84. Sufrin CB, Postlethwaite D, Armstrong MA, Merchant M, Wendt JM, Steinauer JE. Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstet Gynecol 2012;120:1314–21. PMID:23168755 https://doi.org/10.1097/AOG.0b013e318273364c
  85. Tepper NK, Steenland MW, Marchbanks PA, Curtis KM. Hemoglobin measurement prior to initiating copper intrauterine devices: a systematic review. Contraception 2013;87:639–44. PMID:23040123 https://doi.org/10.1016/j.contraception.2012.08.008
  86. Rivera R, Almonte H, Arreola M, et al. The effects of three different regimens of oral contraceptives and three different intrauterine devices on the levels of hemoglobin, serum iron and iron binding capacity in anemic women. Contraception 1983;27:311–27. PMID:6851562 https://doi.org/10.1016/0010-7824(83)90009-4
  87. Effects of contraceptives on hemoglobin and ferritin. Task Force for Epidemiological Research on Reproductive Health, United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland. Contraception 1998;58:262–73. PMID:9883381
  88. Hassan EO, el-Husseini M, el-Nahal N. The effect of 1-year use of the CuT 380A and oral contraceptive pills on hemoglobin and ferritin levels. Contraception 1999;60:101–5. PMID:10592857 https://doi.org/10.1016/S0010-7824(99)00065-7
  89. Calzolari E, Guglielmo R, Viola F, Migliore L. [Hematological parameters and iron therapy in women with IUD’s. Experimental study]. Minerva Ginecol 1981;33:355–62. PMID:7243079
  90. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56–72. PMID:8137626 https://doi.org/10.1016/0010-7824(94)90109-0

    91. Back to Top

  91. Andrade AT, Pizarro E, Shaw ST Jr, Souza JP, Belsey EM, Rowe PJ; World Health Organization. Consequences of uterine blood loss caused by various intrauterine contraceptive devices in South American women. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1988;38:1–18. PMID:3048870 https://doi.org/10.1016/0010-7824(88)90091-1
  92. Blum M, Ariel J, Zacharowitch D. Ferritin, a faithful reflection of iron deficiency in IUD wearers with mild vaginal spotting. Adv Contracept 1991;7:39–42. PMID:1872195 https://doi.org/10.1007/BF01850717
  93. El-sheikha Z, Hamza A, Mahmoud M. Menstrual blood loss of TCu-380 A and TCu-200 B IUDs. Popul Sci 1990;55–62. PMID:12343358
  94. Gallegost AJ, Aznar R, Merino G, Guizer E. Intrauterine devices and menstrual blood loss. A comparative study of eight devices during the first six months of use. Contraception 1978;17:153–61. PMID:630885 https://doi.org/10.1016/0010-7824(78)90071-9
  95. Gao J, Zeng S, Sun BL, et al. Menstrual blood loss, haemoglobin and ferritin concentration of Beijing women wearing steel ring, VCu 200, and TCu 220c IUDs. Contraception 1986;34:559–71. PMID:3829674 https://doi.org/10.1016/S0010-7824(86)80012-9
  96. Goh TH, Hariharan M. Effect of laparoscopic sterilization and insertion of Multiload Cu 250 and Progestasert IUDs on serum ferritin levels. Contraception 1983;28:329–36. PMID:6667621 https://doi.org/10.1016/0010-7824(83)90034-3
  97. Goh TH, Hariharan M, Tan CH. A longitudinal study of serum iron indices and haemoglobin concentration following copper-IUD insertion. Contraception 1980;22:389–95. PMID:7449387 https://doi.org/10.1016/0010-7824(80)90024-4
  98. Guillebaud J, Bonnar J, Morehead J, Matthews A. Menstrual blood-loss with intrauterine devices. Lancet 1976;1:387–90. PMID:55650 https://doi.org/10.1016/S0140-6736(76)90216-6
  99. Haugan T, Skjeldestad FE, Halvorsen LE, Kahn H. A randomized trial on the clinical performance of Nova T380 and Gyne T380 Slimline copper IUDs. Contraception 2007;75:171–6. PMID:17303485 https://doi.org/10.1016/j.contraception.2006.09.005
  100. Kivijärvi A, Timonen H, Rajamäki A, Grönroos M. Iron deficiency in women using modern copper intrauterine devices. Obstet Gynecol 1986;67:95–8. PMID:3940345

    101. Back to Top

  1. Larsson B, Hamberger L, Rybo G. Influence of copper intrauterine contraceptive devices (Cu-7-IUD) on the menstrual blood-loss. Acta Obstet Gynecol Scand 1975;54:315–8. PMID:1199700 https://doi.org/10.3109/00016347509156760
  2. Larsson G, Milsom I, Jonasson K, Lindstedt G, Rybo G. The long-term effects of copper surface area on menstrual blood loss and iron status in women fitted with an IUD. Contraception 1993;48:471–80. PMID:8275696 https://doi.org/10.1016/0010-7824(93)90136-U
  3. Malmqvist R, Petersohn L, Bengtsson LP. Menstrual bleeding with copper-covered intrauterine contraceptive devices. Contraception 1974;9:627–33. PMID:4448089 https://doi.org/10.1016/0010-7824(74)90048-1
  4. Milsom I, Rybo G, Lindstedt G. The influence of copper surface area on menstrual blood loss and iron status in women fitted with an IUD. Contraception 1990;41:271–81. PMID:2323218 https://doi.org/10.1016/0010-7824(90)90068-7
  5. Piedras J, Córdova MS, Pérez-Toral MC, Lince E, Garza-Flores J. Predictive value of serum ferritin in anemia development after insertion of T Cu 220 intrauterine device. Contraception 1983;27:289–97. PMID:6851561 https://doi.org/10.1016/0010-7824(83)90007-0
  6. Sivin I, Alvarez F, Diaz J, et al. Intrauterine contraception with copper and with levonorgestrel: a randomized study of the TCu 380Ag and levonorgestrel 20 mcg/day devices. Contraception 1984;30:443–56. PMID:6440740 https://doi.org/10.1016/0010-7824(84)90036-2
  7. Sivin I, Stern J, Diaz J, et al. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices. Contraception 1987;35:245–55. PMID:3111785 https://doi.org/10.1016/0010-7824(87)90026-6
  8. Tchai BS, Kim SW, Han JH, Im MW. Menstrual blood loss, iron nutriture, and the effects of Alza-T IPCS 52, T-Cu 220C and Lippes Loop D in Korean women. Seoul J Med 1987;28:51–9. PMID:12283693
  9. Wright EA, Kapu MM, Isichei UP. Zinc depletion and menorrhagia in Nigerians using copper T-200 intrauterine device. Trace Elem Med 1989;6:147–9. PMID:12343060
  10. Milsom I, Andersson K, Jonasson K, Lindstedt G, Rybo G. The influence of the Gyne-T 380S IUD on menstrual blood loss and iron status. Contraception 1995;52:175–9. PMID:7587189 https://doi.org/10.1016/0010-7824(95)00163-5

    11. Back to Top

  11. Carroll MD, Fryar CD. Total and high-density lipoprotein cholesterol in adults: United States, 2015–2018. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2020. https://www.cdc.gov/nchs/data/databriefs/db363-h.pdf
  12. Berenson AB, Rahman M, Wilkinson G. Effect of injectable and oral contraceptives on serum lipids. Obstet Gynecol 2009;114:786–94. PMID:19888036 https://doi.org/10.1097/AOG.0b013e3181b76bea
  13. Dilbaz B, Ozdegirmenci O, Caliskan E, Dilbaz S, Haberal A. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception 2010;81:510–4. PMID:20472118 https://doi.org/10.1016/j.contraception.2010.01.014
  14. Nelson AL, Cwiak C. Combined Oral Contraceptives. In: Hatcher RA, Trussel J, Nelson A, Cates W Jr, Kowal D, Policar M, eds. Contraceptive Technology. 20th ed. New York, NY: Ardent Media, Inc; 2011:249–342.
  15. Dragoman M, Curtis KM, Gaffield ME. Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes. Contraception 2016;94:280–7. PMID:26272309 https://doi.org/10.1016/j.contraception.2015.08.002
  16. US Department of Health and Human Services. Summary health statistics for U.S. adults: National Health Interview Survey, 2012. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2014. https://www.cdc.gov/nchs/data/series/sr_10/sr10_260.pdf
  17. CDC. Surveillance for viral hepatitis—United States, 2013. https://www.cdc.gov/hepatitis/statistics/2013surveillance/index.htm
  18. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 2015;107:djv048. Erratum in: J Natl Cancer Inst 2015:107;djv121; J Natl Cancer Inst 2015:107;djv177. PMID:25825511 https://doi.org/10.1093/jnci/djv048
  19. National Cancer Institute. Cancer Stat Facts. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. https://seer.cancer.gov/faststats/selections.php?series=cancer
  20. Watson M, Saraiya M, Benard V, et al. Burden of cervical cancer in the United States, 1998–2003. Cancer 2008;113(Suppl):2855–64. PMID:18980204 https://doi.org/10.1002/cncr.23756

    21. Back to Top

  21. National Center for Health Statistics. Health, United States, 2014. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics. https://www.ncbi.nlm.nih.gov/books/NBK299348/pdf/Bookshelf_NBK299348.pdf
  22. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ 1992;304:809–13. PMID:1392708 https://doi.org/10.1136/bmj.304.6830.809
  23. Coleman JS, Mwachari C, Balkus J, et al. Effect of the levonorgestrel intrauterine device on genital HIV-1 RNA shedding among HIV-1-infected women not taking antiretroviral therapy in Nairobi, Kenya. J Acquir Immune Defic Syndr 2013;63:245–8. PMID:23446496 https://doi.org/10.1097/QAI.0b013e31828decf8
  24. Haddad LB, Cwiak C, Jamieson DJ, et al. Contraceptive adherence among HIV-infected women in Malawi: a randomized controlled trial of the copper intrauterine device and depot medroxyprogesterone acetate. Contraception 2013;88:737–43. PMID:24060297 https://doi.org/10.1016/j.contraception.2013.08.006
  25. Heikinheimo O, Lehtovirta P, Aho I, Ristola M, Paavonen J. The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study. Am J Obstet Gynecol 2011;204:126 e1–4. PMID:21035781 https://doi.org/10.1016/j.ajog.2010.09.002
  26. Heikinheimo O, Lehtovirta P, Suni J, Paavonen J. The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women—effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum Reprod 2006;21:2857–61. PMID:16880227 https://doi.org/10.1093/humrep/del264
  27. Kakaire O, Byamugisha JK, Tumwesigye NM, Gemzell-Danielsson K. Clinical versus laboratory screening for sexually transmitted infections prior to insertion of intrauterine contraception among women living with HIV/AIDS: a randomized controlled trial. Hum Reprod 2015;30:1573–9. PMID:25979373 https://doi.org/10.1093/humrep/dev109
  28. Kovacs A, Wasserman SS, Burns D, et al.; DATRI Study Group; WIHS Study Group. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001;358:1593–601. PMID:11716886 https://doi.org/10.1016/S0140-6736(01)06653-3
  29. Landolt NK, Phanuphak N, Teeratakulpisarn N, et al. Uptake and continuous use of copper intrauterine device in a cohort of HIV-positive women. AIDS Care 2013;25:710–4. PMID:23308374 https://doi.org/10.1080/09540121.2012.752786
  30. Lehtovirta P, Paavonen J, Heikinheimo O. Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women. Contraception 2007;75:37–9. PMID:17161122 https://doi.org/10.1016/j.contraception.2006.09.006

    31. Back to Top

  31. Morrison CS, Sekadde-Kigondu C, Sinei SK, Weiner DH, Kwok C, Kokonya D. Is the intrauterine device appropriate contraception for HIV-1-infected women? BJOG 2001;108:784–90. PMID:11510700 https://doi.org/10.1111/j.1471-0528.2001.00204.x
  32. Mostad SB, Overbaugh J, DeVange DM, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997;350:922–7. PMID:9314871 https://doi.org/10.1016/S0140-6736(97)04240-2
  33. Richardson BA, Morrison CS, Sekadde-Kigondu C, et al. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS 1999;13:2091–7. PMID:10546862 https://doi.org/10.1097/00002030-199910220-00012
  34. Sinei SK, Morrison CS, Sekadde-Kigondu C, Allen M, Kokonya D. Complications of use of intrauterine devices among HIV-1-infected women. Lancet 1998;351:1238–41. PMID:9643743 https://doi.org/10.1016/S0140-6736(97)10319-1
  35. Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007;197:144 e1–8. PMID:17689627 https://doi.org/10.1016/j.ajog.2007.03.031
  36. Stringer EM, Levy J, Sinkala M, et al. HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial. AIDS 2009;23:1377–82. PMID:19448528 https://doi.org/10.1097/QAD.0b013e32832cbca8
  37. Tepper NK, Curtis KM, Nanda K, Jamieson DJ. Safety of intrauterine devices among women with HIV: a systematic review. Contraception 2016;94:713–24. PMID:27343750 https://doi.org/10.1016/j.contraception.2016.06.011
  38. Callahan DG, Garabedian LF, Harney KF, DiVasta AD. Will it hurt? The intrauterine device insertion experience and long-term acceptability among adolescents and young women. J Pediatr Adolesc Gynecol 2019;32:615–21. PMID:31401254 https://doi.org/10.1016/j.jpag.2019.08.004
  39. Hunter TA, Sonalkar S, Schreiber CA, Perriera LK, Sammel MD, Akers AY. Anticipated pain during intrauterine device insertion. J Pediatr Adolesc Gynecol 2020;33:27–32. PMID:31563628 https://doi.org/10.1016/j.jpag.2019.09.007
  40. Potter J, Rubin SE, Sherman P. Fear of intrauterine contraception among adolescents in New York City. Contraception 2014;89:446–50. PMID:24560479 https://doi.org/10.1016/j.contraception.2014.01.011

    41. Back to Top

  41. American College of Obstetricians and Gynecologists. Caring for patients who have experienced trauma: ACOG Committee Opinion, Number 825. Obstet Gynecol 2021;137:e94–9. PMID:33759830 https://doi.org/10.1097/AOG.0000000000004326
  42. Hilden M, Sidenius K, Langhoff-Roos J, Wijma B, Schei B. Women’s experiences of the gynecologic examination: factors associated with discomfort. Acta Obstet Gynecol Scand 2003;82:1030–6. PMID:14616277 https://doi.org/10.1034/j.1600-0412.2003.00253.x
  43. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain 2020;161:1976–82. PMID:32694387 https://doi.org/10.1097/j.pain.0000000000001939
  44. Abu-Zaid A, Alshahrani MS, Albezrah NA, et al. Vaginal dinoprostone versus placebo for pain relief during intrauterine device insertion: a systematic review and meta-analysis of randomised controlled trials. Eur J Contracept Reprod Health Care 2021;26:357–66. PMID:33691549 https://doi.org/10.1080/13625187.2021.1891411
  45. Grimes DA, Schulz KF. Prophylactic antibiotics for intrauterine device insertion: a metaanalysis of the randomized controlled trials. Contraception 1999;60:57–63. PMID:10592851 https://doi.org/10.1016/S0010-7824(99)00071-2
  46. Wilson W, Taubert KA, Gewitz M, et al.; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007;116:1736–54. PMID:17446442 https://doi.org/10.1161/CIRCULATIONAHA.106.183095
  47. Canto De Cetina TE, Canto P, Ordoñez Luna M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception 2001;63:143–6. PMID:11368986 https://doi.org/10.1016/S0010-7824(01)00181-0
  48. Lei ZW, Wu SC, Garceau RJ, et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception 1996;53:357–61. PMID:8773423 https://doi.org/10.1016/0010-7824(96)00085-6
  49. Godfrey EM, Folger SG, Jeng G, Jamieson DJ, Curtis KM. Treatment of bleeding irregularities in women with copper-containing IUDs: a systematic review. Contraception 2013;87:549–66. PMID:23199413 https://doi.org/10.1016/j.contraception.2012.09.006
  50. Toppozada M, Anwar M, Abdel Rahman H, Gaweesh S. Control of IUD-induced bleeding by three non-steroidal anti-inflammatory drugs. Contracept Deliv Syst 1982;3:117–25. PMID:12338165

    51. Back to Top

  51. Toppozada M, El-Attar A, El-Ayyat MA, Khamis Y. Management of uterine bleeding by PGs or their synthesis inhibitors. Adv Prostaglandin Thromboxane Res 1980;8:1459–63. PMID:6769315
  52. Wu S, Wang C, Cheng W, et al. Randomized multi-center study of baofuxin for treatment of bleeding side-effect induced by IUD. Reprod Contracept 2000;11:152–7.
  53. Mercorio F, De Simone R, Di Carlo C, et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Hum Reprod 2003;18:2319–22. PMID:14585881 https://doi.org/10.1093/humrep/deg449
  54. Pedron N, Lozano M, Aznar R. Treatment of hypermenorrhea with mefenamic acid in women using IUDs. Contracept Deliv Syst 1982;3:135–9. PMID:12338167
  55. Pizarro E, Mehech G, Hidalgo M, Muñoz G, Romero C. [Effect of meclofenamic acid on menstruation in hypermenorrheic women using intrauterine devices]. Rev Chil Obstet Ginecol 1988;53:43–56. PMID:3079306
  56. Chinese National IUD Research Working Group. [Prevention and treatment of IUD-induced menorrhagia with antifibrinolytic and antiprostaglandin drugs]. Zhonghua Fu Chan Ke Za Zhi 1987;22:291–4, 312. PMID:3443023
  57. Di Lieto A, Catalano D, Miranda L, Paladini A. Action of a prostaglandin synthetase inhibitor on IUD associated uterine bleeding. Clin Exp Obstet Gynecol 1987;14:41–4. PMID:3102127
  58. Ylikorkala O, Viinikka L. Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. Br J Obstet Gynaecol 1983;90:78–83. PMID:6336951 https://doi.org/10.1111/j.1471-0528.1983.tb06751.x
  59. Pfizer. Cyklokapron (tranexamic acid injection) [Package insert]. New York, NY: Pfizer; 2011.
  60. Ferring Pharmaceuticals. Lysteda (tranexamic acid tablets) [Package insert]. Parsippany, NJ: Ferring Pharmaceuticals; 2011.

    61. Back to Top

  61. Pedrón N, Lozano M, Gallegos AJ. The effect of acetylsalicylic acid on menstrual blood loss in women with IUDs. Contraception 1987;36:295–303. PMID:3677676 https://doi.org/10.1016/0010-7824(87)90099-0
  62. Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002;65:129–32. PMID:11927115 https://doi.org/10.1016/S0010-7824(01)00302-X
  63. van der Heijden PAHH, Tibosch RMG, Geomini PMAJ, et al. What is the best drug treatment for premenopausal women with bleeding irregularities using the levonorgestrel-releasing intrauterine system? A systematic review. Eur J Contracept Reprod Health Care 2020;25:484–91. PMID:32757842 https://doi.org/10.1080/13625187.2020.1797663
  64. Sørdal T, Inki P, Draeby J, O’Flynn M, Schmelter T. Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstet Gynecol 2013;121:934–41. PMID:23635728 https://doi.org/10.1097/AOG.0b013e31828c65d8
  65. Fava M, Peloggia A, Baccaro LF, Castro S, Carvalho N, Bahamondes L. A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. Int J Gynaecol Obstet 2020;149:10–5. PMID:31777949 https://doi.org/10.1002/ijgo.13068
  66. Oderkerk T, vander Heijden P, Tibosch R, Bui B, Geomini P, Bongers M. Treatment of irregular bleeding with oestradiol during long-term levonogestrel-releasing intrauterine system (LNG-IUS) use. Front Womens Health 2019;4:1–3. https://doi.org/10.15761/FWH.1000171
  67. Tepper NK, Steenland MW, Gaffield ME, Marchbanks PA, Curtis KM. Retention of intrauterine devices in women who acquire pelvic inflammatory disease: a systematic review. Contraception 2013;87:655–60. PMID:23040135 https://doi.org/10.1016/j.contraception.2012.08.011
  68. Larsson B, Wennergren M. Investigation of a copper-intrauterine device (Cu-IUD) for possible effect on frequency and healing of pelvic inflammatory disease. Contraception 1977;15:143–9. PMID:837688 https://doi.org/10.1016/0010-7824(77)90012-9
  69. Söderberg G, Lindgren S. Influence of an intrauterine device on the course of an acute salpingitis. Contraception 1981;24:137–43. PMID:7297065 https://doi.org/10.1016/0010-7824(81)90086-X
  70. Teisala K. Removal of an intrauterine device and the treatment of acute pelvic inflammatory disease. Ann Med 1989;21:63–5. PMID:2923706 https://doi.org/10.3109/07853898909149184

    71. Back to Top

  71. Altunyurt S, Demir N, Posaci C. A randomized controlled trial of coil removal prior to treatment of pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol 2003;107:81–4. PMID:12593901 https://doi.org/10.1016/S0301-2115(02)00342-1
  72. Stewart FH, Harper CC, Ellertson CE, Grimes DA, Sawaya GF, Trussell J. Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence. JAMA 2001;285:2232–9. PMID:11325325 https://doi.org/10.1001/jama.285.17.2232
  73. Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008;13(Suppl 1):13–28. PMID:18330814 https://doi.org/10.1080/13625180801959931
  74. Chegini N, Rhoton-Vlasak A, Williams RS. Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding. Fertil Steril 2003;80:564–70. PMID:12969699 https://doi.org/10.1016/S0015-0282(03)00797-0
  75. Grow DR, Reece MT. The role of selective oestrogen receptor modulators in the treatment of endometrial bleeding in women using long-acting progestin contraception. Hum Reprod 2000;15(Suppl 3):30–8. PMID:11041219 https://doi.org/10.1093/humrep/15.suppl_3.30
  76. Hickey M, Fraser IS. Surface vascularization and endometrial appearance in women with menorrhagia or using levonorgestrel contraceptive implants. Implications for the mechanisms of breakthrough bleeding. Hum Reprod 2002;17:2428–34. PMID:12202436 https://doi.org/10.1093/humrep/17.9.2428
  77. Vincent AJ, Salamonsen LA. The role of matrix metalloproteinases and leukocytes in abnormal uterine bleeding associated with progestin-only contraceptives. Hum Reprod 2000;15(Suppl 3):135–43. PMID:11041229 https://doi.org/10.1093/humrep/15.suppl_3.135
  78. White JO, Sullivan MH, Patel L, et al. Prostaglandin production in human endometrium following continuous exposure to low-dose levonorgestrel released from a vaginal ring. Contraception 1991;43:401–12. PMID:1649733 https://doi.org/10.1016/0010-7824(91)90077-S
  79. Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2019;9:CD000400. PMID:31535715 https://doi.org/10.1002/14651858.CD000400.pub4
  80. Shaaban MM, el-Nashar IM, Ghaneimah SA, Gomaa AA, Salah M, Abdel-Aleem AM. Hormonal changes during the first year of use of subdermal levonoregestrel implants, Norplant. Contraception 1984;30:391–405. PMID:6440735 https://doi.org/10.1016/0010-7824(84)90031-3

    81. Back to Top

  81. Faúndes A, Alvarez-Sanchez F, Brache V, Jimenez E, Tejada AS. Hormonal changes associated with bleeding during low dose progestogen contraception delivered by Norplant subdermal implants. Adv Contracept 1991;7:85–94. PMID:1908178 https://doi.org/10.1007/BF01850722
  82. Glasier AF, Wang H, Davie JE, Kelly RW, Critchley HO. Administration of an antiprogesterone up-regulates estrogen receptors in the endometrium of women using Norplant: a pilot study. Fertil Steril 2002;77:366–72. PMID:11821099 https://doi.org/10.1016/S0015-0282(01)02997-1
  83. Helmestam M, Andersson H, Stavreus-Evers A, Brittebo E, Olovsson M. Tamoxifen modulates cell migration and expression of angiogenesis-related genes in human endometrial endothelial cells. Am J Pathol 2012;180:2527–35. PMID:22531128 https://doi.org/10.1016/j.ajpath.2012.02.026
  84. Spitz IM. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 2003;68:981–93. PMID:14667991 https://doi.org/10.1016/j.steroids.2003.08.007
  85. Whitaker LH, Murray AA, Matthews R, et al. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium. Hum Reprod 2017;32:531–43. PMID:28130434 https://doi.org/10.1093/humrep/dew359
  86. Jain JK, Nicosia AF, Nucatola DL, Lu JJ, Kuo J, Felix JC. Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids 2003;68:1115–9. PMID:14668006 https://doi.org/10.1016/S0039-128X(03)00132-6
  87. Lukes AS, Kouides PA, Moore KA. Tranexamic acid: a novel oral formulation for the treatment of heavy menstrual bleeding. Womens Health (Lond Engl) 2011;7:151–8. PMID:21410342 https://doi.org/10.2217/WHE.11.9
  88. Burns FR, Stack MS, Gray RD, Paterson CA. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci 1989;30:1569–75. PMID:2545645
  89. Vernillo AT, Ramamurthy NS, Golub LM, Rifkin BR. The nonantimicrobial properties of tetracycline for the treatment of periodontal disease. Curr Opin Periodontol 1994:111–8. PMID:8032451
  90. Hickey M, d’Arcangues C. Vaginal bleeding disturbances and implantable contraceptives. Contraception 2002;65:75–84. PMID:11861057 https://doi.org/10.1016/S0010-7824(01)00292-X

    91. Back to Top

  91. Buasang K, Taneepanichskul S. Efficacy of celecoxib on controlling irregular uterine bleeding secondary to Jadelle use. J Med Assoc Thai 2009;92:301–7. PMID:19301720
  92. Kaewrudee S, Taneepanichskul S, Jaisamraun U, Reinprayoon D. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use. Contraception 1999;60:25–30. PMID:10549449 https://doi.org/10.1016/S0010-7824(99)00059-1
  93. Phaliwong P, Taneepanichskul S. The effect of mefenamic acid on controlling irregular uterine bleeding second to Implanon use. J Med Assoc Thai 2004;87(Suppl 3):S64–8. PMID:21213495
  94. Upawi SN, Ahmad MF, Abu MA, Ahmad S. Management of bleeding irregularities among etonogestrel implant users: Is combined oral contraceptives pills or nonsteroidal anti-inflammatory drugs the better option? J Obstet Gynaecol Res 2020;46:479–84. PMID:31958877 https://doi.org/10.1111/jog.14195
  95. Archer DF, Philput CB, Levine AS, et al. Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in levonorgestrel subcutaneous implant users. Contraception 2008;78:106–12. PMID:18672110 https://doi.org/10.1016/j.contraception.2008.04.003
  96. Díaz S, Croxatto HB, Pavez M, Belhadj H, Stern J, Sivin I. Clinical assessment of treatments for prolonged bleeding in users of Norplant implants. Contraception 1990;42:97–109. PMID:2117517 https://doi.org/10.1016/0010-7824(90)90094-C
  97. Phupong V, Sophonsritsuk A, Taneepanichskul S. The effect of tranexamic acid for treatment of irregular uterine bleeding secondary to Norplant use. Contraception 2006;73:253–6. PMID:16472565 https://doi.org/10.1016/j.contraception.2005.09.012
  98. Alvarez-Sanchez F, Brache V, Thevenin F, Cochon L, Faundes A. Hormonal treatment for bleeding irregularities in Norplant implant users. Am J Obstet Gynecol 1996;174:919–22. PMID:8633669 https://doi.org/10.1016/S0002-9378(96)70326-5
  99. Guiahi M, McBride M, Sheeder J, Teal S. Short-term treatment of bothersome bleeding for etonogestrel implant users using a 14-day oral contraceptive pill regimen: a randomized controlled trial. Obstet Gynecol 2015;126:508–13. PMID:26181091 https://doi.org/10.1097/AOG.0000000000000974
  100. Hou MY, McNicholas C, Creinin MD. Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial. Eur J Contracept Reprod Health Care 2016;21:361–6. PMID:27419258 https://doi.org/10.1080/13625187.2016.1210122

    101. Back to Top

  1. Witjaksono J, Lau TM, Affandi B, Rogers PA. Oestrogen treatment for increased bleeding in Norplant users: preliminary results. Hum Reprod 1996;11(Suppl 2):109–14. PMID:8982752 https://doi.org/10.1093/humrep/11.suppl_2.109
  2. Boonkasemsanti W, Reinprayoon D, Pruksananonda K, et al. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users. Hum Reprod 1996;11(Suppl 2):115–23. PMID:8982753 https://doi.org/10.1093/humrep/11.suppl_2.115
  3. Abdel-Aleem H, Shaaban OM, Amin AF, Abdel-Aleem AM. Tamoxifen treatment of bleeding irregularities associated with Norplant use. Contraception 2005;72:432–7. PMID:16307966 https://doi.org/10.1016/j.contraception.2005.05.015
  4. Edelman AB, Kaneshiro B, Simmons KB, et al. Treatment of unfavorable bleeding patterns in contraceptive implant users: a randomized controlled trial. Obstet Gynecol 2020;136:323–32. PMID:32649493 https://doi.org/10.1097/AOG.0000000000003896
  5. Simmons KB, Edelman AB, Fu R, Jensen JT. Tamoxifen for the treatment of breakthrough bleeding with the etonogestrel implant: a randomized controlled trial. Contraception 2017;95:198–204. PMID:27725164 https://doi.org/10.1016/j.contraception.2016.10.001
  6. d’Arcangues C, Piaggio G, Brache V, et al.; Study Group on Progestogen-induced Vaginal Bleeding Disturbances. Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, on Norplant-induced prolonged bleeding. Contraception 2004;70:451–62. PMID:15541406 https://doi.org/10.1016/j.contraception.2004.05.012
  7. Cheng L, Zhu H, Wang A, Ren F, Chen J, Glasier A. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod 2000;15:1969–72. PMID:10966997 https://doi.org/10.1093/humrep/15.9.1969
  8. Weisberg E, Hickey M, Palmer D, et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod 2006;21:295–302. PMID:16284061 https://doi.org/10.1093/humrep/dei273
  9. Weisberg E, Hickey M, Palmer D, et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009;24:1852–61. PMID:19369294 https://doi.org/10.1093/humrep/dep081
  10. Zigler RE, Madden T, Ashby C, Wan L, McNicholas C. Ulipristal acetate for unscheduled bleeding in etonogestrel implant users: a randomized controlled trial. Obstet Gynecol 2018;132:888–94. PMID:30130351 https://doi.org/10.1097/AOG.0000000000002810

    11. Back to Top

  11. Subakir SB, Setiadi E, Affandi B, Pringgoutomo S, Freisleben HJ. Benefits of vitamin E supplementation to Norplant users—in vitro and in vivo studies. Toxicology 2000;148:173–8. PMID:10962136 https://doi.org/10.1016/S0300-483X(00)00208-0
  12. Kapp N, Gaffield ME. Initiation of progestogen-only injectables on different days of the menstrual cycle and its effect on contraceptive effectiveness and compliance: a systematic review. Contraception 2013;87:576–82. PMID:22995541 https://doi.org/10.1016/j.contraception.2012.08.017
  13. Petta CA, Faúndes A, Dunson TR, et al. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function. Fertil Steril 1998;70:817–20. PMID:9806559 https://doi.org/10.1016/S0015-0282(98)00309-4
  14. Petta CA, Faundes A, Dunson TR, et al. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus. Fertil Steril 1998;69:252–7. PMID:9496338 https://doi.org/10.1016/S0015-0282(97)00477-9
  15. Siriwongse T, Snidvongs W, Tantayaporn P, Leepipatpaiboon S. Effect of depo-medroxyprogesterone acetate on serum progesterone levels when administered on various cycle days. Contraception 1982;26:487–93. PMID:6218964 https://doi.org/10.1016/0010-7824(82)90147-0
  16. Balkus J, Miller L. Same-day administration of depot-medroxyprogesterone acetate injection: a retrospective chart review. Contraception 2005;71:395–8. PMID:15854642 https://doi.org/10.1016/j.contraception.2004.10.014
  17. Morroni C, Grams M, Tiezzi L, Westhoff C. Immediate monthly combination contraception to facilitate initiation of the depot medroxyprogesterone acetate contraceptive injection. Contraception 2004;70:19–23. PMID:15208048 https://doi.org/10.1016/j.contraception.2004.02.007
  18. Nelson AL, Katz T. Initiation and continuation rates seen in 2-year experience with same day injections of DMPA. Contraception 2007;75:84–7. PMID:17241834 https://doi.org/10.1016/j.contraception.2006.09.007
  19. Rickert VI, Tiezzi L, Lipshutz J, León J, Vaughan RD, Westhoff C. Depo Now: preventing unintended pregnancies among adolescents and young adults. J Adolesc Health 2007;40:22–8. PMID:17185202 https://doi.org/10.1016/j.jadohealth.2006.10.018
  20. Sneed R, Westhoff C, Morroni C, Tiezzi L. A prospective study of immediate initiation of depo medroxyprogesterone acetate contraceptive injection. Contraception 2005;71:99–103. PMID:15707558 https://doi.org/10.1016/j.contraception.2004.08.014

    21. Back to Top

  21. Tepper NK, Curtis KM, Steenland MW, Marchbanks PA. Blood pressure measurement prior to initiating hormonal contraception: a systematic review. Contraception 2013;87:631–8. PMID:23063336 https://doi.org/10.1016/j.contraception.2012.08.025
  22. Azeez O, Kulkarni A, Kuklina EV, Kim SY, Cox S. Hypertension and diabetes in non-pregnant women of reproductive age in the United States. Prev Chronic Dis 2019;16:E146. PMID:31651378 https://doi.org/10.5888/pcd16.190105
  23. Diab KM, Zaki MM. Contraception in diabetic women: comparative metabolic study of Norplant, depot medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A. J Obstet Gynaecol Res 2000;26:17–26. PMID:10761326 https://doi.org/10.1111/j.1447-0756.2000.tb01195.x
  24. Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA 1994;271:1099–102. PMID:8151852 https://doi.org/10.1001/jama.1994.03510380055037
  25. Grigoryan OR, Grodnitskaya EE, Andreeva EN, Chebotnikova TV, Melnichenko GA. Use of the NuvaRing hormone-releasing system in late reproductive-age women with type 1 diabetes mellitus. Gynecol Endocrinol 2008;24:99–104. PMID:18210334 https://doi.org/10.1080/09513590701708795
  26. Kahn HS, Curtis KM, Marchbanks PA. Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk. Diabetes Care 2003;26:216–25. PMID:12502684 https://doi.org/10.2337/diacare.26.1.216
  27. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2009;(4):CD006133. PMID:19821355 https://doi.org/10.1002/14651858.CD006133.pub3
  28. Rogovskaya S, Rivera R, Grimes DA, et al. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. Obstet Gynecol 2005;105:811–5. PMID:15802410 https://doi.org/10.1097/01.AOG.0000156301.11939.56
  29. Troisi RJ, Cowie CC, Harris MI. Oral contraceptive use and glucose metabolism in a national sample of women in the United States. Am J Obstet Gynecol 2000;183:389–95. PMID:10942475 https://doi.org/10.1067/mob.2000.105909
  30. Blickstein D, Blickstein I. Oral contraception and thrombophilia. Curr Opin Obstet Gynecol 2007;19:370–6. PMID:17625421 https://doi.org/10.1097/GCO.0b013e32821642e6

    31. Back to Top

  31. Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv 2023;7:7101–38. PMID:37195076 https://doi.org/10.1182/bloodadvances.2023010177
  32. Wu O, Greer IA. Is screening for thrombophilia cost-effective? Curr Opin Hematol 2007;14:500–3. PMID:17934357 https://doi.org/10.1097/MOH.0b013e32825f5318
  33. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006;10:1–110. PMID:16595080 https://doi.org/10.3310/hta10110
  34. Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv 2023;7:7101–38. PMID:37195076 https://doi.org/10.1182/bloodadvances.2023010177
  35. Kennedy CE, Yeh PT, Gaffield ML, Brady M, Narasimhan M. Self-administration of injectable contraception: a systematic review and meta-analysis. BMJ Glob Health 2019;4:e001350. PMID:31179026 https://doi.org/10.1136/bmjgh-2018-001350
  36. World Health Organization. WHO consolidated guideline on self-care interventions for health: sexual and reproductive health and rights. Web annex: GRADE tables Geneva, Switzerland: World Health Organization; 2017. https://iris.who.int/bitstream/handle/10665/325487/WHO-RHR-19.13-eng.pdf?sequence=1&isAllowed=y
  37. Bonny AE, Secic M, Cromer B. Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate. Obstet Gynecol 2011;117:793–7. PMID:21422849 https://doi.org/10.1097/AOG.0b013e31820f387c
  38. Le YL, Rahman M, Berenson AB. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. Obstet Gynecol 2009;114:279–84. PMID:19622988 https://doi.org/10.1097/AOG.0b013e3181af68b2
  39. Risser WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. J Adolesc Health 1999;24:433–6. PMID:10401972 https://doi.org/10.1016/S1054-139X(98)00151-7
  40. Paulen ME, Curtis KM. When can a woman have repeat progestogen-only injectables—depot medroxyprogesterone acetate or norethisterone enantate? Contraception 2009;80:391–408. PMID:19751863 https://doi.org/10.1016/j.contraception.2009.03.023

    41. Back to Top

  41. Pardthaisong T. Return of fertility after use of the injectable contraceptive Depo Provera: up-dated data analysis. J Biosoc Sci 1984;16:23–34. PMID:6230362 https://doi.org/10.1017/S0021932000014760
  42. Schwallie PC, Assenzo JR. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception 1974;10:181–202. PMID:4419530 https://doi.org/10.1016/0010-7824(74)90073-0
  43. Steiner MJ, Kwok C, Stanback J, et al. Injectable contraception: what should the longest interval be for reinjections? Contraception 2008;77:410–4. PMID:18477489 https://doi.org/10.1016/j.contraception.2008.01.017
  44. Bassol S, Garza-Flores J, Cravioto MC, et al. Ovarian function following a single administration of depo-medroxyprogesterone acetate (DMPA) at different doses. Fertil Steril 1984;42:216–22. PMID:6235131 https://doi.org/10.1016/S0015-0282(16)48016-7
  45. Fotherby K, Koetsawang S, Mathrubutham M. Pharmacokinetic study of different doses of Depo Provera. Contraception 1980;22:527–36. PMID:6451351 https://doi.org/10.1016/0010-7824(80)90105-5
  46. Fotherby K, Saxena BN, Shrimanker K, et al. A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate. Fertil Steril 1980;34:131–9. PMID:7409232 https://doi.org/10.1016/S0015-0282(16)44895-8
  47. Garza-Flores J, Cardenas S, Rodríguez V, Cravioto MC, Diaz-Sanchez V, Perez-Palacios G. Return to ovulation following the use of long-acting injectable contraceptives: a comparative study. Contraception 1985;31:361–6. PMID:3159544 https://doi.org/10.1016/0010-7824(85)90004-6
  48. Jain J, Dutton C, Nicosia A, Wajszczuk C, Bode FR, Mishell DR Jr. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception 2004;70:11–8. PMID:15208047 https://doi.org/10.1016/j.contraception.2004.01.011
  49. Lan PT, Aedo AR, Landgren BM, Johannisson E, Diczfalusy E. Return of ovulation following a single injection of depo-medroxyprogesterone acetate: a pharmacokinetic and pharmacodynamic study. Contraception 1984;29:1–18. PMID:6234145 https://doi.org/10.1016/0010-7824(84)90054-4
  50. Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab 1977;44:32–8. PMID:833262 https://doi.org/10.1210/jcem-44-1-32

    51. Back to Top

  51. Saxena BN, Dusitsin N, Tankeyoon M, Chaudhury RR. Return of ovulation after the cessation of depot-medroxy progesterone acetate treatment in Thai women. J Med Assoc Thai 1980;63:66–9. PMID:7365344
  52. Toh YC, Jain J, Rahnny MH, Bode FR, Ross D. Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women. Clin Ther 2004;26:1845–54. PMID:15639696 https://doi.org/10.1016/j.clinthera.2004.11.013
  53. Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception 2006;74:234–8. PMID:16904417 https://doi.org/10.1016/j.contraception.2006.03.008
  54. Dempsey A, Roca C, Westhoff C. Vaginal estrogen supplementation during Depo-Provera initiation: a randomized controlled trial. Contraception 2010;82:250–5. PMID:20705153 https://doi.org/10.1016/j.contraception.2010.04.003
  55. Abdel-Aleem H, d’Arcangues C, Vogelsong KM, Gulmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev 2007;Cd003449. PMID:23828544 https://doi.org/10.1002/14651858.CD003449.pub4
  56. Harel Z, Biro F, Kollar L, Riggs S, Flanagan P, Vaz R. Supplementation with vitamin C and/or vitamin B(6) in the prevention of Depo-Provera side effects in adolescents. J Pediatr Adolesc Gynecol 2002;15:153–8. PMID:12106752 https://doi.org/10.1016/S1083-3188(02)00148-1
  57. Nathirojanakun P, Taneepanichskul S, Sappakitkumjorn N. Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users. Contraception 2006;73:584–7. PMID:16730488 https://doi.org/10.1016/j.contraception.2005.09.013
  58. Tantiwattanakul P, Taneepanichskul S. Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users. Contraception 2004;70:277–9. PMID:15451330 https://doi.org/10.1016/j.contraception.2004.04.003
  59. Said S, Sadek W, Rocca M, et al. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation. Hum Reprod 1996;11(Suppl 2):1–13. PMID:8982739 https://doi.org/10.1093/humrep/11.suppl_2.1
  60. Sadeghi-Bazargani H, Ehdaeivand F, Arshi S, Eftekhar H, Sezavar H, Amanati L. Low-dose oral contraceptive to re-induce menstrual bleeding in amenorrheic women on DMPA treatment: a randomized clinical trial. Med Sci Monit 2006;12:CR420–5. PMID:17006401

    61. Back to Top

  61. Brahmi D, Curtis KM. When can a woman start combined hormonal contraceptives (CHCs)? A systematic review. Contraception 2013;87:524–38. PMID:23153903 https://doi.org/10.1016/j.contraception.2012.09.010
  62. Edwards SM, Zieman M, Jones K, Diaz A, Robilotto C, Westhoff C. Initiation of oral contraceptives—start now! J Adolesc Health 2008;43:432–6. PMID:18848670 https://doi.org/10.1016/j.jadohealth.2008.06.008
  63. Westhoff C, Heartwell S, Edwards S, et al. Initiation of oral contraceptives using a quick start compared with a conventional start: a randomized controlled trial. Obstet Gynecol 2007;109:1270–6. PMID:17540797 https://doi.org/10.1097/01.AOG.0000264550.41242.f2
  64. Westhoff C, Morroni C, Kerns J, Murphy PA. Bleeding patterns after immediate vs. conventional oral contraceptive initiation: a randomized, controlled trial. Fertil Steril 2003;79:322–9. PMID:12568841 https://doi.org/10.1016/S0015-0282(02)04680-0
  65. Baerwald AR, Olatunbosun OA, Pierson RA. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. Contraception 2004;70:371–7. PMID:15504375 https://doi.org/10.1016/j.contraception.2004.05.006
  66. Baerwald AR, Pierson RA. Ovarian follicular development during the use of oral contraception: a review. J Obstet Gynaecol Can 2004;26:19–24. PMID:14715122 https://doi.org/10.1016/S1701-2163(16)30692-2
  67. Duijkers IJ, Klipping C, Verhoeven CH, Dieben TO. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study. Hum Reprod 2004;19:2668–73. PMID:15333593 https://doi.org/10.1093/humrep/deh493
  68. Killick S, Eyong E, Elstein M. Ovarian follicular development in oral contraceptive cycles. Fertil Steril 1987;48:409–13. PMID:3114009 https://doi.org/10.1016/S0015-0282(16)59407-2
  69. Molloy BG, Coulson KA, Lee JM, Watters JK. “Missed pill” conception: fact or fiction? Br Med J (Clin Res Ed) 1985;290:1474–5. PMID:3922540 https://doi.org/10.1136/bmj.290.6480.1474-a
  70. Mulders TM, Dieben TO, Bennink HJ. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod 2002;17:2594–9. PMID:12351535 https://doi.org/10.1093/humrep/17.10.2594

    71. Back to Top

  71. Schwartz JL, Creinin MD, Pymar HC, Reid L. Predicting risk of ovulation in new start oral contraceptive users. Obstet Gynecol 2002;99:177–82. PMID:11814492 https://doi.org/10.1016/S0029-7844(01)01676-3
  72. Sitavarin S, Jaisamrarn U, Taneepanichskul S. A randomized trial on the impact of starting day on ovarian follicular activity in very low dose oral contraceptive pills users. J Med Assoc Thai 2003;86:442–8. PMID:12859101
  73. Taylor DR, Anthony FW, Dennis KJ. Suppression of ovarian function by Microgynon 30 in day 1 and day 5 “starters”. Contraception 1986;33:463–71. PMID:3757512 https://doi.org/10.1016/S0010-7824(86)80005-1
  74. Smith SK, Kirkman RJ, Arce BB, McNeilly AS, Loudon NB, Baird DT. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis. Contraception 1986;34:513–22. PMID:3102162 https://doi.org/10.1016/0010-7824(86)90060-0
  75. Lara-Torre E, Schroeder B. Adolescent compliance and side effects with Quick Start initiation of oral contraceptive pills. Contraception 2002;66:81–5. PMID:12204779 https://doi.org/10.1016/S0010-7824(02)00326-8
  76. Murthy AS, Creinin MD, Harwood B, Schreiber CA. Same-day initiation of the transdermal hormonal delivery system (contraceptive patch) versus traditional initiation methods. Contraception 2005;72:333–6. PMID:16246657 https://doi.org/10.1016/j.contraception.2005.05.009
  77. Westhoff C, Osborne LM, Schafer JE, Morroni C. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive. Obstet Gynecol 2005;106:89–96. PMID:15994622 https://doi.org/10.1097/01.AOG.0000164483.13326.59
  78. Yeshaya A, Orvieto R, Kaplan B, et al. Flexible starting schedule for oral contraception: effect on the incidence of breakthrough bleeding and compliance. Eur J Contracept Reprod Health Care 1998;3:121–3. PMID:9853202 https://doi.org/10.3109/13625189809051414
  79. Yeshaya A, Orvieto R, Kauschansky A, et al. A delayed starting schedule of oral contraception: the effect on the incidence of breakthrough bleeding and compliance in women. Eur J Contracept Reprod Health Care 1996;1:263–5. PMID:9678125 https://doi.org/10.3109/13625189609150668
  80. Westhoff C, Kerns J, Morroni C, Cushman LF, Tiezzi L, Murphy PA. Quick start: novel oral contraceptive initiation method. Contraception 2002;66:141–5. PMID:12384200 https://doi.org/10.1016/S0010-7824(02)00351-7

    81. Back to Top

  81. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997;349:1202–9. PMID:9130941 https://doi.org/10.1016/S0140-6736(97)02358-1
  82. Dunn N, Thorogood M, Faragher B, et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 1999;318:1579–83. PMID:10364115 https://doi.org/10.1136/bmj.318.7198.1579
  83. Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997;56:129–40. PMID:9347202 https://doi.org/10.1016/S0010-7824(97)00118-2
  84. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996;348:498–505. PMID:8757151 https://doi.org/10.1016/S0140-6736(95)12393-8
  85. Heinemann LA, Lewis MA, Spitzer WO, Thorogood M, Guggenmoos-Holzmann I, Bruppacher R; Transnational Research Group on Oral Contraceptives and the Health of Young Women. Thromboembolic stroke in young women. A European case-control study on oral contraceptives. Contraception 1998;57:29–37. PMID:9554248 https://doi.org/10.1016/S0010-7824(97)00204-7
  86. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996;348:505–10. PMID:8757152 https://doi.org/10.1016/S0140-6736(95)12394-6
  87. White KO, Westhoff C. The effect of pack supply on oral contraceptive pill continuation: a randomized controlled trial. Obstet Gynecol 2011;118:615–22. PMID:21860291 https://doi.org/10.1097/AOG.0b013e3182289eab
  88. Foster DG, Parvataneni R, de Bocanegra HT, Lewis C, Bradsberry M, Darney P. Number of oral contraceptive pill packages dispensed, method continuation, and costs. Obstet Gynecol 2006;108:1107–14. PMID:17077231 https://doi.org/10.1097/01.AOG.0000239122.98508.39
  89. Foster DG, Hulett D, Bradsberry M, Darney P, Policar M. Number of oral contraceptive pill packages dispensed and subsequent unintended pregnancies. Obstet Gynecol 2011;117:566–72. PMID:21343759 https://doi.org/10.1097/AOG.0b013e3182056309
  90. Chin-Quee DS, Cuthbertson C, Janowitz B. Over-the-counter pill provision: evidence from Jamaica. Stud Fam Plann 2006;37:99–110. PMID:16832984 https://doi.org/10.1111/j.1728-4465.2006.00089.x

    91. Back to Top

  91. Zapata LB, Steenland MW, Brahmi D, Marchbanks PA, Curtis KM. Effect of missed combined hormonal contraceptives on contraceptive effectiveness: a systematic review. Contraception 2013;87:685–700. PMID:23083527 https://doi.org/10.1016/j.contraception.2012.08.035
  92. Anttila L, Kunz M, Marr J. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive. Contraception 2009;80:445–51. PMID:19835718 https://doi.org/10.1016/j.contraception.2009.03.013
  93. Chowdhury V, Joshi UM, Gopalkrishna K, Betrabet S, Mehta S, Saxena BN. ‘Escape’ ovulation in women due to the missing of low dose combination oral contraceptive pills. Contraception 1980;22:241–7. PMID:7438752 https://doi.org/10.1016/S0010-7824(80)80003-5
  94. Christin-Maitre S, Serfaty D, Chabbert-Buffet N, Ochsenbein E, Chassard D, Thomas JL. Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17β-estradiol (NOMAC/E2): a double-blind, randomized study. Hum Reprod 2011;26:1338–47. PMID:21421664 https://doi.org/10.1093/humrep/der058
  95. Creinin MD, Lippman JS, Eder SE, Godwin AJ, Olson W. The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 micro g ethinyl estradiol versus monophasic levonorgestrel/20 micro g ethinyl estradiol. Contraception 2002;66:147–52. PMID:12384201 https://doi.org/10.1016/S0010-7824(02)00344-X
  96. Dinger J, Do Minh T, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011;117:33–40. PMID:21213475 https://doi.org/10.1097/AOG.0b013e31820095a2
  97. Elomaa K, Lähteenmäki P. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment. Contraception 1999;60:275–9. PMID:10717779 https://doi.org/10.1016/S0010-7824(99)00094-3
  98. Elomaa K, Rolland R, Brosens I, et al. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation. Am J Obstet Gynecol 1998;179:41–6. PMID:9704763 https://doi.org/10.1016/S0002-9378(98)70249-2
  99. Endrikat J, Wessel J, Rosenbaum P, Düsterberg B. Plasma concentrations of endogenous hormones during one regular treatment cycle with a low-dose oral contraceptive and during two cycles with deliberate omission of two tablets. Gynecol Endocrinol 2004;18:318–26. PMID:15497494 https://doi.org/10.1080/0951359042000199869
  100. Hamilton CJ, Hoogland HJ. Longitudinal ultrasonographic study of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake. Am J Obstet Gynecol 1989;161:1159–62. PMID:2686444 https://doi.org/10.1016/0002-9378(89)90655-8

    101. Back to Top

  1. Hedon B, Cristol P, Plauchut A, et al. Ovarian consequences of the transient interruption of combined oral contraceptives. Int J Fertil 1992;37:270–6. PMID:1358837
  2. Killick SR. Ovarian follicles during oral contraceptive cycles: their potential for ovulation. Fertil Steril 1989;52:580–2. PMID:2680616 https://doi.org/10.1016/S0015-0282(16)60967-6
  3. Killick SR, Bancroft K, Oelbaum S, Morris J, Elstein M. Extending the duration of the pill-free interval during combined oral contraception. Adv Contracept 1990;6:33–40. PMID:2378291 https://doi.org/10.1007/BF01849485
  4. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008;78:16–25. PMID:18555813 https://doi.org/10.1016/j.contraception.2008.02.019
  5. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005;71:409–16. PMID:15914128 https://doi.org/10.1016/j.contraception.2004.12.005
  6. Landgren BM, Csemiczky G. The effect of follicular growth and luteal function of “missing the pill”. A comparison between a monophasic and a triphasic combined oral contraceptive. Contraception 1991;43:149–59. PMID:1828225 https://doi.org/10.1016/0010-7824(91)90042-E
  7. Landgren BM, Diczfalusy E. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles. Contraception 1984;29:437–46. PMID:6430642 https://doi.org/10.1016/0010-7824(84)90017-9
  8. Letterie GS. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation. Contraception 1998;57:39–44. PMID:9554249 https://doi.org/10.1016/S0010-7824(97)00205-9
  9. Letterie GS, Chow GE. Effect of “missed” pills on oral contraceptive effectiveness. Obstet Gynecol 1992;79:979–82. PMID:1579326
  10. Morris SE, Groom GV, Cameron ED, Buckingham MS, Everitt JM, Elstein M. Studies on low dose oral contraceptives: plasma hormone changes in relation to deliberate pill (‘Microgynon 30’) omission. Contraception 1979;20:61–9. PMID:477318 https://doi.org/10.1016/0010-7824(79)90045-3

    11. Back to Top

  11. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception 2007;75:16–22. PMID:17161118 https://doi.org/10.1016/j.contraception.2006.08.004
  12. Nuttall ID, Elstein M, McCafferty E, Seth J, Cameron ED. The effect of ethinyl estradiol 20 mcg and levonorgestrel 250 mcg on the pituitary-ovarian function during normal tablet-taking and when tablets are missed. Contraception 1982;26:121–35. PMID:6814817 https://doi.org/10.1016/0010-7824(82)90081-6
  13. Pierson RA, Archer DF, Moreau M, Shangold GA, Fisher AC, Creasy GW. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril 2003;80:34–42. PMID:12849799 https://doi.org/10.1016/S0015-0282(03)00556-9
  14. Rible RD, Taylor D, Wilson ML, Stanczyk FZ, Mishell DR Jr. Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate. Contraception 2009;79:182–8. PMID:19185670 https://doi.org/10.1016/j.contraception.2008.10.005
  15. Schlaff WD, Lynch AM, Hughes HD, Cedars MI, Smith DL. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am J Obstet Gynecol 2004;190:943–51. PMID:15118618 https://doi.org/10.1016/j.ajog.2004.02.012
  16. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996;54:71–7. PMID:8842582 https://doi.org/10.1016/0010-7824(96)00137-0
  17. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 1999;72:115–20. PMID:10428158 https://doi.org/10.1016/S0015-0282(99)00205-8
  18. Wang E, Shi S, Cekan SZ, Landgren BM, Diczfalusy E. Hormonal consequences of “missing the pill”. Contraception 1982;26:545–66. PMID:6820336 https://doi.org/10.1016/0010-7824(82)90131-7
  19. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary–ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006;74:100–3. PMID:16860046 https://doi.org/10.1016/j.contraception.2006.02.006
  20. Abrams LS, Skee DM, Natarajan J, et al. Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise. J Clin Pharmacol 2001;41:1301–9. PMID:11762557 https://doi.org/10.1177/00912700122012887

    21. Back to Top

  21. Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006;74:451–7. PMID:17157101 https://doi.org/10.1016/j.contraception.2006.07.004
  22. Bjarnadóttir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002;186:389–95. PMID:11904596 https://doi.org/10.1067/mob.2002.121103
  23. Brucker C, Karck U, Merkle E. Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing: results of clinical experience in Germany. Eur J Contracept Reprod Health Care 2008;13:31–8. PMID:17853162 https://doi.org/10.1080/13625180701577122
  24. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002;100:585–93. PMID:12220783 https://doi.org/10.1016/S0029-7844(02)02124-5
  25. Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 2001;75:865–70. PMID:11334895 https://doi.org/10.1016/S0015-0282(01)01689-2
  26. Guilbert E, Boroditsky R, Black A, et al.; HPV Consensus Guidelines Committee Chairs; SOGC Project Officer; HPV Consensus Guidelines Committee. Canadian consensus guideline on continuous and extended hormonal contraception, 2007. J Obstet Gynaecol Can 2007;29(Suppl 2):S1–3. PMID:17761109 https://doi.org/10.1016/S1701-2163(16)32526-9
  27. Wiegratz I, Stahlberg S, Manthey T, et al. Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception 2011;84:133–43. PMID:21757054 https://doi.org/10.1016/j.contraception.2011.01.002
  28. Hubacher D, Fortney J. Follow-up visits after IUD insertion. Are more better? J Reprod Med 1999;44:801–6. PMID:10509305
  29. Godfrey EM, Whiteman MK, Curtis KM. Treatment of unscheduled bleeding in women using extended- or continuous-use combined hormonal contraception: a systematic review. Contraception 2013;87:567–75. PMID:23044386 https://doi.org/10.1016/j.contraception.2012.08.005
  30. Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol 2006;195:935–41. PMID:16647684 https://doi.org/10.1016/j.ajog.2006.02.048

    31. Back to Top

  31. Sulak PJ, Smith V, Coffee A, Witt I, Kuehl AL, Kuehl TJ. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol 2008;112:563–71. PMID:18757653 https://doi.org/10.1097/AOG.0b013e3181842071
  32. Kaneshiro B, Edelman A, Carlson N, Morgan K, Nichols M, Jensen J. Treatment of unscheduled bleeding in continuous oral contraceptive users with doxycycline: a randomized controlled trial. Obstet Gynecol 2010;115:1141–9. PMID:20502283 https://doi.org/10.1097/AOG.0b013e3181e0119c
  33. McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994;50(Suppl 1):S1–195. PMID:10226677 https://doi.org/10.1016/0010-7824(94)90113-9
  34. Duijkers IJ, Heger-Mahn D, Drouin D, Skouby S. A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen. Eur J Contracept Reprod Health Care 2015;20:419–27. PMID:26073333 https://doi.org/10.3109/13625187.2015.1044082
  35. Duijkers IJM, Heger-Mahn D, Drouin D, Colli E, Skouby S. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception 2016;93:303–9. PMID:26708301 https://doi.org/10.1016/j.contraception.2015.12.007
  36. Exeltis USA. Slynd (drospirenone) [Package insert]. Florham Park, NJ: Exeltis USA; 2019.
  37. Arévalo M, Jennings V, Sinai I. Efficacy of a new method of family planning: the Standard Days Method. Contraception 2002;65:333–8. PMID:12057784 https://doi.org/10.1016/S0010-7824(02)00288-3
  38. Arévalo M, Sinai I, Jennings V. A fixed formula to define the fertile window of the menstrual cycle as the basis of a simple method of natural family planning. Contraception 1999;60:357–60. PMID:10715371 https://doi.org/10.1016/S0010-7824(99)00106-7
  39. Wilcox AJ, Dunson DB, Weinberg CR, Trussell J, Baird DD. Likelihood of conception with a single act of intercourse: providing benchmark rates for assessment of post-coital contraceptives. Contraception 2001;63:211–5. PMID:11376648 https://doi.org/10.1016/S0010-7824(01)00191-3
  40. Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod 2012;27:1994–2000. PMID:22570193 https://doi.org/10.1093/humrep/des140

    41. Back to Top

  41. Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 2010;375:555–62. PMID:20116841 https://doi.org/10.1016/S0140-6736(10)60101-8
  42. Raymond E, Taylor D, Trussell J, Steiner MJ. Minimum effectiveness of the levonorgestrel regimen of emergency contraception. Contraception 2004;69:79–81. PMID:14720626 https://doi.org/10.1016/j.contraception.2003.09.013
  43. Jatlaoui TC, Curtis KM. Safety and effectiveness data for emergency contraceptive pills among women with obesity: a systematic review. Contraception 2016;94:605–11. PMID:27234874 https://doi.org/10.1016/j.contraception.2016.05.002
  44. Fine P, Mathé H, Ginde S, Cullins V, Morfesis J, Gainer E. Ulipristal acetate taken 48–120 hours after intercourse for emergency contraception. Obstet Gynecol 2010;115:257–63. PMID:20093897 https://doi.org/10.1097/AOG.0b013e3181c8e2aa
  45. Dada OA, Godfrey EM, Piaggio G, von Hertzen H; Nigerian Network for Reproductive Health Research and Training. A randomized, double-blind, noninferiority study to compare two regimens of levonorgestrel for emergency contraception in Nigeria. Contraception 2010;82:373–8. PMID:20851232 https://doi.org/10.1016/j.contraception.2010.06.004
  46. Ellertson C, Evans M, Ferden S, et al. Extending the time limit for starting the Yuzpe regimen of emergency contraception to 120 hours. Obstet Gynecol 2003;101:1168–71. PMID:12798519 https://doi.org/10.1016/S0029-7844(03)00352-1
  47. Ngai SW, Fan S, Li S, et al. A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception. Hum Reprod 2005;20:307–11. PMID:15567882 https://doi.org/10.1093/humrep/deh583
  48. Rodrigues I, Grou F, Joly J. Effectiveness of emergency contraceptive pills between 72 and 120 hours after unprotected sexual intercourse. Am J Obstet Gynecol 2001;184:531–7. PMID:11262449 https://doi.org/10.1067/mob.2001.111102
  49. von Hertzen H, Piaggio G, Ding J, et al.; WHO Research Group on Post-ovulatory Methods of Fertility Regulation. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002;360:1803–10. PMID:12480356 https://doi.org/10.1016/S0140-6736(02)11767-3
  50. Piaggio G, Kapp N, von Hertzen H. Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials. Contraception 2011;84:35–9. PMID:21664508 https://doi.org/10.1016/j.contraception.2010.11.010

    51. Back to Top

  51. Rodriguez MI, Curtis KM, Gaffield ML, Jackson E, Kapp N. Advance supply of emergency contraception: a systematic review. Contraception 2013;87:590–601. PMID:23040139 https://doi.org/10.1016/j.contraception.2012.09.011
  52. Banh C, Rautenberg T, Duijkers I, et al. The effects on ovarian activity of delaying versus immediately restarting combined oral contraception after missing three pills and taking ulipristal acetate 30 mg. Contraception 2020;102:145–51. PMID:32474062 https://doi.org/10.1016/j.contraception.2020.05.013
  53. Brache V, Cochon L, Duijkers IJ, et al. A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. Hum Reprod 2015;30:2785–93. PMID:26405263 https://doi.org/10.1093/humrep/dev241
  54. Cameron ST, Berger C, Michie L, Klipping C, Gemzell-Danielsson K. The effects on ovarian activity of ulipristal acetate when ‘quickstarting’ a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study. Hum Reprod 2015;30:1566–72. PMID:25994664 https://doi.org/10.1093/humrep/dev115
  55. Edelman AB, Jensen JT, McCrimmon S, Messerle-Forbes M, O’Donnell A, Hennebold JD. Combined oral contraceptive interference with the ability of ulipristal acetate to delay ovulation: A prospective cohort study. Contraception 2018;98:463–6. PMID:30118684 https://doi.org/10.1016/j.contraception.2018.08.003
  56. Rodriguez MI, Godfrey EM, Warden M, Curtis KM. Prevention and management of nausea and vomiting with emergency contraception: a systematic review. Contraception 2013;87:583–9. PMID:23121827 https://doi.org/10.1016/j.contraception.2012.09.031
  57. Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 2006;108:1089–97. PMID:17077229 https://doi.org/10.1097/01.AOG.0000239440.02284.45
  58. Farajkhoda T, Khoshbin A, Enjezab B, Bokaei M, Karimi Zarchi M. Assessment of two emergency contraceptive regimens in Iran: levonorgestrel versus the Yuzpe. Niger J Clin Pract 2009;12:450–2. PMID:20329690
  59. Ho PC, Kwan MS. A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception. Hum Reprod 1993;8:389–92. PMID:8473453 https://doi.org/10.1093/oxfordjournals.humrep.a138057
  60. Arowojolu AO, Okewole IA, Adekunle AO. Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. Contraception 2002;66:269–73. PMID:12413624 https://doi.org/10.1016/S0010-7824(02)00337-2

    61. Back to Top

  61. Ragan RE, Rock RW, Buck HW. Metoclopramide pretreatment attenuates emergency contraceptive-associated nausea. Am J Obstet Gynecol 2003;188:330–3. PMID:12592235 https://doi.org/10.1067/mob.2003.90
  62. Raymond EG, Creinin MD, Barnhart KT, Lovvorn AE, Rountree RW, Trussell J. Meclizine for prevention of nausea associated with use of emergency contraceptive pills: a randomized trial. Obstet Gynecol 2000;95:271–7. PMID:10674593 https://doi.org/10.1016/S0029-7844(99)00550-5
  63. Peterson HB. Sterilization. Obstet Gynecol 2008;111:189–203. PMID:18165410 https://doi.org/10.1097/01.AOG.0000298621.98372.62
  64. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell J. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996;174:1161–8, discussion 1168–70. PMID:8623843 https://doi.org/10.1016/S0002-9378(96)70658-0
  65. Lawrie TA, Nardin JM, Kulier R, Boulvain M. Techniques for the interruption of tubal patency for female sterilisation. Cochrane Database Syst Rev 2011; (2):CD003034. PMID:21328258 https://doi.org/10.1002/14651858.CD003034.pub2
  66. Sharlip ID, Belker AM, Honig S, et al.; American Urological Association. Vasectomy: AUA guideline. J Urol 2012;188(Suppl):2482–91. PMID:23098786 https://doi.org/10.1016/j.juro.2012.09.080
  67. Bedford JM, Zelikovsky G. Viability of spermatozoa in the human ejaculate after vasectomy. Fertil Steril 1979;32:460–3. PMID:488436 https://doi.org/10.1016/S0015-0282(16)44305-0
  68. Edwards IS. Earlier testing after vasectomy, based on the absence of motile sperm. Fertil Steril 1993;59:431–6. PMID:8425641 https://doi.org/10.1016/S0015-0282(16)55706-9
  69. Jouannet P, David G. Evolution of the properties of semen immediately following vasectomy. Fertil Steril 1978;29:435–41. PMID:648646 https://doi.org/10.1016/S0015-0282(16)43220-6
  70. Labrecque M, Hays M, Chen-Mok M, Barone MA, Sokal D. Frequency and patterns of early recanalization after vasectomy. BMC Urol 2006;6:25. PMID:16984640 https://doi.org/10.1186/1471-2490-6-25

    71. Back to Top

  71. Alderman PM. The lurking sperm. A review of failures in 8879 vasectomies performed by one physician. JAMA 1988;259:3142–4. PMID:3367490 https://doi.org/10.1001/jama.1988.03720210032024
  72. Black T, Francome C. The evolution of the Marie Stopes electrocautery no-scalpel vasectomy procedure. J Fam Plann Reprod Health Care 2002;28:137–8. PMID:16259831 https://doi.org/10.1783/147118902101196270
  73. Davies AH, Sharp RJ, Cranston D, Mitchell RG. The long-term outcome following “special clearance” after vasectomy. Br J Urol 1990;66:211–2. PMID:2390708 https://doi.org/10.1111/j.1464-410X.1990.tb14907.x
  74. Philp T, Guillebaud J, Budd D. Late failure of vasectomy after two documented analyses showing azoospermic semen. Br Med J (Clin Res Ed) 1984;289:77–9. PMID:6428685 https://doi.org/10.1136/bmj.289.6437.77
  75. Philp T, Guillebaud J, Budd D. Complications of vasectomy: review of 16,000 patients. Br J Urol 1984;56:745–8. PMID:6534499 https://doi.org/10.1111/j.1464-410X.1984.tb06161.x
  76. Belker AM, Sexter MS, Sweitzer SJ, Raff MJ. The high rate of noncompliance for post-vasectomy semen examination: medical and legal considerations. J Urol 1990;144:284–6. PMID:2374193 https://doi.org/10.1016/S0022-5347(17)39433-8
  77. Chawla A, Bowles B, Zini A. Vasectomy follow-up: clinical significance of rare nonmotile sperm in postoperative semen analysis. Urology 2004;64:1212–5. PMID:15596199 https://doi.org/10.1016/j.urology.2004.07.007
  78. Labrecque M, Bédard L, Laperrière L. [Efficacy and complications associated with vasectomies in two clinics in the Quebec region]. Can Fam Physician 1998;44:1860–6. PMID:9789666
  79. Labrecque M, Nazerali H, Mondor M, Fortin V, Nasution M. Effectiveness and complications associated with 2 vasectomy occlusion techniques. J Urol 2002;168:2495–8, discussion 2498. PMID:12441948 https://doi.org/10.1016/S0022-5347(05)64176-6
  80. Maatman TJ, Aldrin L, Carothers GG. Patient noncompliance after vasectomy. Fertil Steril 1997;68:552–5. PMID:9314934 https://doi.org/10.1016/S0015-0282(97)00251-3

    81. Back to Top

  81. Dhar NB, Jones JS, Bhatt A, Babineau D. A prospective evaluation of the impact of scheduled follow-up appointments with compliance rates after vasectomy. BJU Int 2007;99:1094–7. PMID:17233802 https://doi.org/10.1111/j.1464-410X.2006.06725.x
  82. Hillard PJ, Berek JS, Barss VA, et al. Guidelines for Women’s Health Care: a resource manual. 3rd ed. Washington, DC: American College of Obstetricians and Gynecologists; 2007.
  83. Shifren JL, Gass ML; NAMS Recommendations for Clinical Care of Midlife Women Working Group. The North American Menopause Society recommendations for clinical care of midlife women. Menopause 2014;21:1038–62. PMID:25225714 https://doi.org/10.1097/GME.0000000000000319
  84. te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002;8:141–54. PMID:12099629 https://doi.org/10.1093/humupd/8.2.141
  85. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009;30:465–93. PMID:19589949 https://doi.org/10.1210/er.2009-0006
  86. Wood JW. Fecundity and natural fertility in humans. Oxf Rev Reprod Biol 1989;11:61–109. PMID:2697833
  87. Balasch J, Gratacós E. Delayed childbearing: effects on fertility and the outcome of pregnancy. Curr Opin Obstet Gynecol 2012;24:187–93. PMID:22450043 https://doi.org/10.1097/GCO.0b013e3283517908
  88. Bateman BT, Simpson LL. Higher rate of stillbirth at the extremes of reproductive age: a large nationwide sample of deliveries in the United States. Am J Obstet Gynecol 2006;194:840–5. PMID:16522422 https://doi.org/10.1016/j.ajog.2005.08.038
  89. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol 2010;116:1302–9. PMID:21099595 https://doi.org/10.1097/AOG.0b013e3181fdfb11
  90. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339(aug13 2):b2890. PMID:19679613 https://doi.org/10.1136/bmj.b2890

    91. Back to Top

  91. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ 2011;343):d6423. PMID:22027398 https://doi.org/10.1136/bmj.d6423
  92. Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Farmer RD. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000;5:265–74. PMID:11245554 https://doi.org/10.1080/13625180008500402
  93. Slone D, Shapiro S, Kaufman DW, Rosenberg L, Miettinen OS, Stolley PD. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med 1981;305:420–4. PMID:7254279 https://doi.org/10.1056/NEJM198108203050802
  94. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001;345:1787–93. PMID:11752354 https://doi.org/10.1056/NEJMoa003216
  95. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713–27. PMID:8656904 https://doi.org/10.1016/S0140-6736(96)90806-5
  96. Gill JK, Press MF, Patel AV, Bernstein L. Oral contraceptive use and risk of breast carcinoma in situ (United States). Cancer Causes Control 2006;17:1155–62. PMID:17006721 https://doi.org/10.1007/s10552-006-0056-0
  97. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish Women’s Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2002;11:1375–81. PMID:12433714
  98. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025–32. PMID:12087137 https://doi.org/10.1056/NEJMoa013202
  99. Newcomb PA, Longnecker MP, Storer BE, et al. Recent oral contraceptive use and risk of breast cancer (United States). Cancer Causes Control 1996;7:525–32. PMID:8877050 https://doi.org/10.1007/BF00051885
  100. Rosenberg L, Palmer JR, Rao RS, et al. Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol 1996;143:25–37. PMID:8533744 https://doi.org/10.1093/oxfordjournals.aje.a008654

    101. Back to Top

  101. Rosenberg L, Zhang Y, Coogan PF, Strom BL, Palmer JR. A case-control study of oral contraceptive use and incident breast cancer. Am J Epidemiol 2009;169:473–9. PMID:19074777 https://doi.org/10.1093/aje/kwn360
  102. Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 2000;151:396–403. PMID:10695598 https://doi.org/10.1093/oxfordjournals.aje.a010219

    103. Back to Top

Print
Content Source:
National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP); Division of Reproductive Health